deltatrials
Completed PHASE1 INTERVENTIONAL 4-arm NCT03914443

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial

Sponsor: Fiverings Co., Ltd.

Conditions Locally Advanced Esophageal Squamous Cell Carcinoma
Interventions 5-FU CDDP DTX Nivolumab
Updated 11 times since 2019 Last updated: May 27, 2025 Started: May 7, 2019 Primary completion: Mar 31, 2025 Completion: Mar 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Locally Advanced Esophageal Squamous Cell Carcinoma, this trial is completed. The trial is conducted by Fiverings Co., Ltd. and has accumulated 11 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2019 – ~Sep 2019 · 4 months · monthly snapshotRecruiting~Sep 2019 – ~Oct 2020 · 13 months · monthly snapshotRecruiting~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotActive Not Recruiting~May 2022 – ~Nov 2022 · 6 months · monthly snapshotRecruiting~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshotActive Not Recruiting~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshotActive Not Recruiting~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotActive Not Recruiting~Jun 2025 – present · 13 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Apr 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

▶ Show 6 earlier versions

  1. Nov 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. May 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  3. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Sep 2019 — Oct 2020 [monthly]

    Recruiting PHASE1

  6. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fiverings Co., Ltd.
  • National Cancer Center, Japan
  • Ono Pharmaceutical Co. Ltd
Data source: National Cancer Center, Japan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations